Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates

Mostrar otras versiones (1)

Many different vaccine candidates against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of COVID-19, are currently approved and under development. Vaccine platforms vary from mRNA vaccines to viral-vectored vaccines, and several candidates have been shown to pro...

Descripción completa

Detalles Bibliográficos
Autores principales: van Doremalen, Neeltje, Fischer, Robert J., Schulz, Jonathan E., Holbrook, Myndi G., Smith, Brian J., Lovaglio, Jamie, Petsch, Benjamin, Munster, Vincent J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402814/
https://www.ncbi.nlm.nih.gov/pubmed/34452509
http://dx.doi.org/10.3390/v13081645

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402814/
https://www.ncbi.nlm.nih.gov/pubmed/34452509
http://dx.doi.org/10.3390/v13081645

Ejemplares similares